5163 POSTER Quality of Life of Women With Breast Cancer Treated in Adjuvant Setting With Tamoxifen or Aromatase Inhibitors

Background: To determine the quality of life of women with early breast cancer treated with Tamoxifen, Letrozole, Anastrazole, Exemestane, after 2 years of treatment. Materials and Methods: A total of 237 women treated in the period 2001–2009 with adjuvant hormonotherapy, were selected to complete the EORTC-C30 and EORTC BR-23 questionnaire. From these women, 115 patients were treated with Tamoxifen and 122 have received aromatase inhibitors: 60 patients have received letrozole, 29 patients anastrazole and 33 patients exemestane. The women had completed the questionnaires after 2 years of hormonal treatment. The primary end point was the comparison of global health status among the groups receiving tamoxifen, letrozole, anastrazole and exemestane. The secondary end point was the analysis of functional scales, emotional scales, cognitive scales and symptom scales of every hormonal treatment group. Results: The assessments available for analysis were in proportion of 88% from questionnaire completion target. There were no differences between the tamoxifen group and the aromatase inhibitors group (letrozole, anastrazole and exemestane) after 2 years of hormonal therapy. Evaluating separately the scales, there is a superiority of the group receiving aromatase inhibitors (anastrazole, letrozole and exemestane) comparing with tamoxifen group regarding symptom scale (sexual function and fatigability) and emotional scale. Among the three groups treated with letrozole, anastrazole and exemestane, was found a statistically significant difference in symptom scale (nausea, dizziness) in favour of anastrazole compared with letrozole. Conclusions: After two years of adjuvant hormonal treatment, the treatment with tamoxifen or aromatase inhibitors has a similar overall impact regarding quality of life. The statistic significant differences appears to be related with symptom scale and emotional scale, where aromatase inhibitors are superior.